Friday 6 November 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue: +14.5%
EPS: −43.6%
Free cash flow: +28.9%
Total debt: +142.7%

Quarter to September 2026, against a year earlier

110.08 3.52 −3.10%

Follow ABT

Alert me

Market cap: $196.6B
P/E: 42.3×
Fwd P/E: 35.1×
Dividend yield: 2.22%
F-score: 5/9
Altman Z: 5.61
Beneish M: −2.50
Dividend safety: 62/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Abbott Laboratories (ABT) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Abbott Laboratories (ABT) trades at a price to free cash flow of 25.2×. Over the past ten years it has ranged from 19.5× (May 2026) to 44.3× (November 2020); the current reading is higher than 26% of that period. That is below the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ABT/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Abbott Laboratories price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ABT/metrics/price-to-free-cash-flow">Abbott Laboratories (ABT) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	29.5×	(4.81%)
FY2024	31.0×	(17.98%)
FY2023	37.8×	53.49%
FY2022	24.6×	(14.79%)
FY2021	28.9×	(14.82%)
FY2020	33.9×	(0.67%)
FY2019	34.1×	31.73%
FY2018	25.9×	12.37%
FY2017	23.1×	(16.74%)
FY2016	27.7×	(23.47%)

Period	Price to free cash flow	Change
Sep 2026	22.0×	8.92%
Jun 2026	20.2×	(16.76%)
Mar 2026	24.2×	(17.80%)
Dec 2025	29.5×	(12.56%)
43 more quarters	Free account

Against its own ten years

Low 19.5× High 44.3×

Ten-year median 30.4×

Current reading's percentile 26

Company	Price to free cash flow
PHG Koninklijke Philips N.V. compare	14.1×
BSX Boston Scientific Corporation compare	19.3×
GEHC GE HealthCare Technologies Inc. compare	19.9×
MDT Medtronic PLC compare	21.8×
ABT Abbott Laboratories	25.2×
STE STERIS plc compare	26.4×
DXCM DexCom, Inc. compare	28.8×
SYK Stryker Corporation compare	28.9×
EW Edwards Lifesciences Corporation compare	41.5×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Abbott Laboratories (ABT) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ABT

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ABT

Stockrow Weekly